What Illinois Patients Should Know About Ozempic Gastroparesis and Medical Documentation

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Science to Occupational Risk

If you or a loved one has developed persistent nausea, vomiting, or abdominal pain after taking Ozempic, you may be wondering how to connect these symptoms to the medication. Decades of pharmacovigilance have established that careful documentation of symptom onset and progression is critical for understanding drug-related adverse events. This page outlines the medical records timeline for Ozempic-associated gastroparesis in Illinois, helping you track key clinical events.

Understanding Gastroparesis and Its Link to Ozempic

Gastroparesis is a chronic disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, where a delay in emptying is confirmed after a standardized meal. The condition can significantly impair quality of life and may require dietary modifications, medications, or even surgical interventions. Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes mellitus. Its pharmacology involves slowing gastric emptying, which contributes to its glucose-lowering effects but also underlies many gastrointestinal adverse reactions. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Specific adverse reactions reported in ≥5% of Ozempic-treated patients included nausea (15.8% for 0.5 mg, 20.3% for 1 mg), vomiting (5.0% for 0.5 mg, 9.2% for 1 mg), diarrhea (8.5% for 0.5 mg, 8.8% for 1 mg), abdominal pain (7.3% for 0.5 mg, 5.7% for 1 mg), and constipation (5.0% for 0.5 mg, 3.1% for 1 mg) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The mechanistic pathway linking Ozempic to gastroparesis involves its action as a GLP-1 receptor agonist, which slows gastric motility. While this effect is intended to improve glycemic control, it can become pathological in susceptible individuals, leading to clinically significant delayed gastric emptying. The reported gastrointestinal adverse reactions, including nausea, vomiting, and abdominal pain, are consistent with gastroparesis symptoms. However, the prescribing information does not explicitly list gastroparesis as a specific adverse reaction, nor does it provide detailed warnings about the risk of developing this condition. The warnings and cautions section primarily addresses hypersensitivity reactions, such as anaphylaxis and angioedema, which have been reported with Ozempic and other GLP-1 receptor agonists (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The adequacy of warnings regarding Ozempic and gastroparesis is a key consideration for affected patients, as the label may not sufficiently alert prescribers and patients to the potential for severe, persistent gastrointestinal dysfunction.

Statute of Limitations for Ozempic Claims in Illinois

For patients in Illinois who have developed gastroparesis after using Ozempic, the statute of limitations is a critical factor in pursuing legal claims. In Illinois, personal injury claims generally must be filed within two years from the date the injury was discovered or should have been discovered through reasonable diligence. This discovery rule applies to cases where the harm is not immediately apparent, such as when symptoms develop gradually after exposure. The timeline between exposure to Ozempic and documented harm is variable; some patients may experience symptoms during dose escalation, while others may develop gastroparesis after months or years of use. The onset of nausea, vomiting, and abdominal pain during treatment should prompt consideration of gastroparesis, and a formal diagnosis via gastric emptying scintigraphy is necessary to confirm the condition. Patients who have been diagnosed with gastroparesis and believe it is linked to Ozempic should consult with a legal professional to determine the applicable filing deadline, as delays could bar recovery. Settlement-related considerations for affected patients include the need to document the timing of Ozempic use, the onset of symptoms, and the diagnosis of gastroparesis. Medical records, including prescription histories, clinical notes, and diagnostic test results, are essential to establish a causal link. The evidence from clinical trials shows a clear dose-response relationship for gastrointestinal adverse reactions, with higher doses associated with increased frequency of nausea, vomiting, and diarrhea (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). This data may support claims that the manufacturer failed to adequately warn about the risk of gastroparesis. However, settlements are not guaranteed, and each case depends on individual circumstances, including the strength of the medical evidence and the timing of the claim relative to the statute of limitations. In summary, patients in Illinois who have developed gastroparesis after using Ozempic should be aware of the two-year statute of limitations from the date of discovery of the injury. The pharmacological mechanism of Ozempic, which slows gastric emptying, provides a plausible link to gastroparesis, and clinical trial data demonstrate a high incidence of gastrointestinal adverse reactions. The adequacy of warnings in the prescribing information is a central issue, as the label does not specifically address gastroparesis. Affected individuals should seek prompt medical evaluation and legal advice to preserve their rights.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in Illinois?

In Illinois, personal injury claims generally must be filed within two years from the date the injury was discovered or should have been discovered through reasonable diligence. This discovery rule applies to cases where the harm is not immediately apparent, such as when symptoms develop gradually after exposure. Patients diagnosed with gastroparesis linked to Ozempic should consult a legal professional to determine the applicable filing deadline.

How does Ozempic cause gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism to improve glycemic control. In susceptible individuals, this effect can become pathological, leading to clinically significant delayed gastric emptying consistent with gastroparesis. Clinical trial data show a high incidence of gastrointestinal adverse reactions such as nausea, vomiting, and abdominal pain, which are symptoms of gastroparesis (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed Ozempic Label

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.